Skip to content
Clinical Trials – home
Research site

Ziekenhuis Amstelland

The Netherlands Laan Van De Helende Meesters 8, 1186 AM Amstelveen, The Netherlands

  • 8 trials recruiting
  • Atrial fibrillation · Arteriosclerosis · Hormone receptor positive HER2 negative breast cancer
  • Adult patients

About Specializations

Ziekenhuis Amstelland in Amstelveen, The Netherlands specialises in clinical trials of conditions such as Atrial fibrillation, Arteriosclerosis, Hormone receptor positive HER2 negative breast cancer, Heart failure with preserved ejection fraction, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases at Ziekenhuis Amstelland

Research at this hospital in Cardiology focuses on cardiovascular diseases, especially atherosclerotic cardiovascular disease, atrial fibrillation, and broader outcomes linked to heart and vascular risk. The trials are designed to test new treatment strategies, improve prevention, and evaluate whether therapies can reduce major events such as heart attack, stroke, and cardiovascular death.

  • ASCVD prevention and reduction of major cardiovascular events
  • Atrial fibrillation and stroke prevention after acute stress-related episodes
  • Cardiovascular risk reduction in people with type 2 diabetes or overweight

Several studies also examine whether newer medicines can improve long-term heart and vascular outcomes when added to standard care.

Neoplasms and Cancer Treatment Research

The site is active in oncology research across several neoplasms, including breast cancer, metastatic colorectal cancer, and diffuse large B-cell lymphoma. These trials aim to refine treatment choices, explore treatment de-escalation where appropriate, and assess whether targeted or immune-based approaches can improve outcomes for people with difficult-to-treat cancers.

  • Breast cancer, including triple negative breast cancer and HR-positive, HER2-negative disease
  • Metastatic colorectal cancer and treatment intensity optimization
  • Diffuse large B-cell lymphoma and prevention of treatment-related heart problems

This research combines efforts to improve cancer control while also considering safety, quality of life, and the balance between treatment benefit and burden.

Female Urogenital Diseases and Pregnancy Complications

Clinical studies in this area include research on infertility and reproductive health, with the goal of improving diagnostic and treatment pathways for women trying to conceive. The work also reflects interest in practical interventions that may support better fertility-related care in everyday clinical settings.

  • Infertility and evaluation of fertility-related procedures
  • Research aimed at improving the chances of conception leading to live birth
  • Comparing approaches that may help guide reproductive care more effectively

At Ziekenhuis Amstelland, this field adds a reproductive health dimension to a portfolio that is otherwise strongly centered on cardiovascular and cancer research.

Hemic and Lymphatic Diseases

The hematology research portfolio includes studies in multiple myeloma and diffuse large B-cell lymphoma. These trials are focused on improving disease control, exploring treatment sequencing, and reducing complications from therapy, especially when patients need effective treatment over a longer period.

  • Multiple myeloma and strategies for treatment-free intervals
  • DLBCL and prevention of heart damage linked to cancer therapy
  • Evaluating whether treatment approaches can preserve effectiveness while limiting toxicity

This area shows a clear interest in balancing cancer treatment benefit with safety, particularly in patients who may already face elevated cardiovascular risk.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Laan Van De Helende Meesters 81186 AM AmstelveenThe Netherlands
Recruiting now
8 trials
Conditions studied
22

More sites in AmstelveenThe Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

18 clinical trials

Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Hamilton Health Sciences Corporation
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Capecitabine
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Atrial fibrillation

Not yet recruiting
Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Etripamil
  • Sponsor:Milestone Pharmaceuticals Inc.
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Arteriosclerosis

Not recruiting
Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.